Business · 1 sources covering this

Nuvalent shares surge 39% after UK's GSK agrees to buy the cancer drugmaker for $10.6 billion

The deal comes at a time of biotech dealmaking frenzy, driven by looming patent cliffs, newly buoyant public markets and drugmakers' race to bolster pipelines.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 0 C · 1 R

How 1 sources are covering this

CNBCLean R·1h ago
Nuvalent shares surge 39% after UK's GSK agrees to buy the cancer drugmaker for $10.6 billion
The deal comes at a time of biotech dealmaking frenzy, driven by looming patent cliffs, newly buoyant public markets and drugmakers' race to bolster pipelines.
Read at CNBC →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/a835a65ccf2447d187a111519b0d002b1bb57d86"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Nuvalent shares surge 39% after UK's GSK agrees to buy the cancer drugmaker for $10.6 billion"></iframe>

Nuvalent shares surge 39% after UK's GSK agrees to buy the cancer drugmaker for $10.6 billion

How 1 sources are covering this

Nuvalent shares surge 39% after UK's GSK agrees to buy the cancer drugmaker for $10.6 billion

More from Business

KBW upgrades Toll, citing the K-shaped housing market favoring the 'affluent'

Trump booed before Knicks lose to Spurs at Madison Square Garden in NBA Finals Game 3

51% of U.S. adults say the American Dream is out of reach for most people right now: CNBC survey

Trump says Iran deal could be reached in 'two or three days' and Strait of Hormuz will reopen 'immediately'

Reader

Trust & legal

Across the network